GSK Cervarix gets standard review
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryGlaxoSmithKline's BLA for Cervarix gets 10-month standard review, setting a January 2008 user fee date for the human papilloma virus vaccine. The firm submitted the vaccine March 29 with a request for a priority review (1Pharmaceutical Approvals Monthly April 2007, In Brief). The decision gives Merck additional time to establish Gardasil, which launched in June 2006, as the only vaccine on the market to prevent human papilloma virus infection and associated diseases, such as cervical cancer. GSK hopes to position Cervarix as a superior product; a head-to-head trial comparing Cervarix to Gardasil is ongoing (2Pharmaceutical Approvals Monthly February 2007, p. 21). In April, Merck submitted an sBLA seeking additional claims for Gardasil for protection against vaginal and vulvar cancers...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.